What is the Most Vital Part of an Effective Psychedelic Treatment?


Ryan Allway

June 24th, 2020

App, Exclusive, Psychedelics, Top News


 

Millions of people have had a psychedelic experience at some point in their life and with new FDA approved medicines and regulatory changes millions more will soon be able to as well. However, without support, it can be challenging to understand and integrate these experiences.

Psychedelic substances are not magic bullets, they are only one tool in the toolbelt of transformational healing and expansion of consciousness. Psychedelics can show people the way and illuminate the pathway towards better mental wellbeing but each person using them needs to be willing to do the work and have the commitment to actually change. 

Psychedelic integration is designed to help people plan, prepare, and make sense of psychedelic experiences. Individuals who have participated in a therapeutic psychedelic treatment can benefit from a more comprehensive interpretation of their experience.

Click on the image to hear Rick Doblin, founder of MAPS, share what the ideal integrative process looks like after taking a psychedelic and how to create the conditions to have the most therapeutic experience as possible.

Psychedelic Therapies will revolutionize mental health 

MDMA as a treatment for post-traumatic stress disorder is in Phase 3 clinical trial and is expected to be approved very soon to treat the over 300 million people affected with the condition. Psilocybin for depressive disorders has two drugs in Phase 2 with patient populations over 322 million. All of these treatments are being fast-tracked by the FDA and once approved there will be a major need for a convenient and confidential integration ( psychedelic aftercare ) solution. Currently, there are 90+ psychedelic clinics but that number is growing with companies expanding to be able to meet the upcoming demand. 

Mindleap Health: At the Convergence of Tech, Mental Health, and Science

Mindleap Health is at the forefront of this industry with its digital telehealth platform focused on the psychedelic therapy industry. Mindleap has recognized that there is an unmet need for people to access psychedelic integration specialists and is creating the world’s first platform focusing on psychedelic aftercare. 

Click here to learn more about investing in MindLeap and download an investor presentation

The company’s unique strategy was re-affirmed when it was acquired last week by Mydecine Innovations Group (CNSX: MYCO) (OTCMKTS: MYCOF)  a life sciences company focused on the development and commercialization of products and services that contribute to improved health and wellbeing with a specific focus on psychedelic medicine. 

The tools Mindleap is building are the first of their kind to allow the patient to monitor, record, and track their mood and habits (both positive and negative) along with providing access to modern health services, namely integrated coaching to translate psychedelic experiences into positive change.

The system is completely secure and compliant with HIPAA and GDPR mandates and is being developed by a world-class development team with a proven track record. 

Finally, Digital Mental Healthcare

As a society, we are becoming more familiar with digital healthcare. Electronic medical records are now the norm. The Covid-19 pandemic has resulted in more usage of video visits to doctors as people sheltered in place to prevent virus spread. A crisis being a catalyst is certainly unfortunate, but it did just make e-visits more mainstream as doctors and patients alike embraced social distancing.

Apropos, already valued at $31.46 billion in 2018, the global telemedicine market is expected to grow at a 19.3% rate by 2025, indicating that adoption is only going to keep accelerating.

Mindleap’s comprehensive platform, expected to launch at the end of summer, includes video visits, appointment scheduling and payment solutions.

Mindleap is also capitalizing on the world’s love of digital technologies, such as smartphones and connected wearable devices, in a newer science dubbed digital phenotyping. By passively collecting data (e.g. sleep patterns, exercise, social patterns), outcomes can be predicted using Artificial Intelligence and Machine Learning. This information subsequently helps healthcare providers optimize support.

The MindLeap App

Click here to learn more about investing in MindLeap and download an investor presentation

It is the epitome of the purpose of Big Data to anonymously help the greater cause by aggregating massive amounts of info. It’s very valuable from both financial and humanitarian perspectives.

The market opportunity as a first mover is tremendous, to say the least. There are more than 577,000 mental health professionals and over 13,000 behavioral health clinics in the U.S. to treat the more than 45 million Americans that have a mental illness.

To put this market opportunity into perspective, consider Livongo. The company has made a splash on Wall Street ($7.4 billion market cap) with an application connecting diabetics to physicians with the strategy that better engagement will promote better health. There are fewer diabetics (~34 million) in the U.S. than people with mental illness.

We’re at a Tipping Point

Thankfully, awareness is growing about the very real medicinal usefulness of psilocybin and other psychedelics. Indeed, they remain illegal as Schedule I drugs currently, but positions are beginning to soften to encourage clinical research. Oakland and Denver have already decriminalized magic mushrooms and over 100 other cities are considering similar action.

Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.

The next logical progression is providing patients with the best support possible to help them achieve meaningful changes to their quality of life. That’s exactly what Mindleap Health – and now Mydecine Innovations Group – is bringing to the table by changing the shape of the aftercare model.

Click here to learn more about investing in MindLeap and download an investor presentation

MindLeap Health Company Contact: 

Nik Vassev

Founder & CEO

[email protected]  

https://mindleap.health/

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading